<br>OSM 在炎症性疾病中的临床相关性：全面综述,Frontiers in Immunology

当前位置： X-MOL 学术 › Front. Immunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

OSM 在炎症性疾病中的临床相关性：全面综述
Frontiers in Immunology ( IF 5.7 ) Pub Date : 2023-09-29 , DOI: 10.3389/fimmu.2023.1239732
Cody L Wolf ₁ , Clyde Pruett ₂ , Darren Lighter ₂ , Cheryl L Jorcyk _{1,

2}

Affiliation

制瘤素 M (OSM) 是一种多效细胞因子，参与多种炎症反应，如伤口愈合、肝再生和骨重塑。作为细胞因子白细胞介素 6 (IL-6) 家族的成员，OSM 结合共享受体 gp130，募集 OSMRβ 或 LIFRβ，并激活多种信号通路，包括 JAK/STAT、MAPK、JNK 和 PI3K/ AKT 途径。自 1986 年发现以来，OSM 已被确定为多种炎症性疾病的重要诱因，包括关节炎、炎症性肠病、肺和皮肤病、心血管疾病以及最近的 COVID-19。此外，OSM 还针对多种癌症类型进行了广泛研究，包括乳腺癌、宫颈癌、卵巢癌、睾丸癌、结肠癌、胃肠道癌、脑癌、肺癌、皮肤癌以及其他癌症。虽然 OSM 已被认为是这些疾病的重要诱因，并且研究表明 OSM 抑制可有效治疗或减轻症状，但很少有治疗方法成功进入临床试验，而且尚未获得 FDA 批准用于治疗。在这篇综述中，我们概述了 OSM 在包括癌症在内的多种炎症性疾病中发挥的作用，并概述了以前和当前开发 OSM 信号传导抑制剂的策略。

"点击查看英文标题和摘要"

The clinical relevance of OSM in inflammatory diseases: a comprehensive review

Oncostatin M (OSM) is a pleiotropic cytokine involved in a variety of inflammatory responses such as wound healing, liver regeneration, and bone remodeling. As a member of the interleukin-6 (IL-6) family of cytokines, OSM binds the shared receptor gp130, recruits either OSMRβ or LIFRβ, and activates a variety of signaling pathways including the JAK/STAT, MAPK, JNK, and PI3K/AKT pathways. Since its discovery in 1986, OSM has been identified as a significant contributor to a multitude of inflammatory diseases, including arthritis, inflammatory bowel disease, lung and skin disease, cardiovascular disease, and most recently, COVID-19. Additionally, OSM has also been extensively studied in the context of several cancer types including breast, cervical, ovarian, testicular, colon and gastrointestinal, brain,lung, skin, as well as other cancers. While OSM has been recognized as a significant contributor for each of these diseases, and studies have shown OSM inhibition is effective at treating or reducing symptoms, very few therapeutics have succeeded into clinical trials, and none have yet been approved by the FDA for treatment. In this review, we outline the role OSM plays in a variety of inflammatory diseases, including cancer, and outline the previous and current strategies for developing an inhibitor for OSM signaling.

更新日期：2023-09-29

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南